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Cholesterol esterification in high density lipoproteins (HDLs) by lecithin:cholesterol
acyltransferase (LCAT) promotes unesterified cholesterol (UC) transfer from red cell
membranes to plasma in vitro. However, it does not explain the transfer of UC from
most peripheral cells to interstitial fluid in vivo, as HDLs in afferent peripheral lymph are
enriched in UC. Having already reported that the endogenous cholesterol esterification
rate (ECER) in lymph is only 5% of that in plasma, we have now explored the underlying
mechanism. In peripheral lymph from 20 healthy men, LCAT concentration, LCAT
activity (assayed using an optimized substrate), and LCAT specific activity averaged,
respectively, 11.8, 10.3, and 84.9% of plasma values. When recombinant human LCAT
was added to lymph, the increments in enzyme activity were similar to those when
LCAT was added to plasma. Addition of apolipoprotein AI (apo AI), fatty acid-free
albumin, Intralipid, or the d < 1.006 g/ml plasma fraction had no effect on ECER. During
incubation of lymph plus plasma, the ECER was similar to that observed with buffer plus
plasma. When lymph was added to heat-inactivated plasma, the ECER was 11-fold
greater than with lymph plus buffer. Addition of discoidal proteoliposomes of apo AI
and phosphatidycholine (PC) to lymph increased ECER 10-fold, while addition of apo
AI/PC/UC disks did so by only six-fold. We conclude that the low ECER in lymph is due
to a property of the HDLs, seemingly substrate inhibition of LCAT by excess cell-derived
UC. This is reversed when lymph enters plasma, consequent upon redistribution of UC
from lymph HDLs to plasma lipoproteins.
Keywords: apolipoprotein AI, lecithin:cholesterol acyltransferase, high density lipoproteins, lymph, interstitial
fluid
INTRODUCTION
Glomset et al. (1966) showed that the unesterified cholesterol (UC) of high density lipoproteins
(HDLs) is the optimum physiologic substrate for lecithin:cholesterol acyltransferase (LCAT) in
plasma. He also showed that cholesterol esterification in HDLs promotes the transfer of UC from
red cell membranes to plasma HDLs in vitro (Glomset, 1970; Glomset and Norum, 1973). On
this basis, he hypothesized that the HDL-LCAT system provides the mechanism by which UC is
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drawn from peripheral cells to HDLs for delivery to the liver
and subsequent elimination. However, later observations seemed
to conflict with this concept. In humans and mice with genetic
LCAT deficiencies, for example, excess cholesterol was found to
be restricted to specific sites, including red blood cells, renal
glomeruli, and the spleen (Stokke et al., 1974; Lambert et al.,
2001). Based on studies in transgenic mice, Alam et al. (2001)
and Tanigawa et al. (2009) concluded that variations in LCAT
gene expression had little or no effect on reverse cholesterol
transport. Reports that the rate of esterification of UC is much
lower in peripheral lymph than in plasma (Dory et al., 1983;
Miller et al., 2013) also questioned the role of LCAT in cholesterol
removal from most cells. Confirmation that LCAT cannot be
rate-limiting was provided by demonstrations that the UC/CE
ratio in lymph HDLs exceeds that in plasma HDLs (Reichl et al.,
1980; Nanjee et al., 2000b), and that the former include disks
devoid of core lipids (Nanjee et al., 2001) similar to those seen
in the plasma of LCAT-deficient subjects (Glomset et al., 1980).
While this line of research was progressing, others discovered
the role of ABCA1 transporters in mediating the egress of UC
from cells to lipid-poor apo AI particles (Oram and Heinecke,
2005).
The explanation of the profound suppression of cholesterol
esterification in HDLs once they have transferred from plasma
across endothelium into the interstitial fluid is not known.
Apolipoprotein (apo) AI, the principal cofactor of LCAT
(Fielding et al., 1972), has been shown to be present at a
concentration of about one fifth that in plasma (Nanjee et al.,
2000b), but there are no published data on LCAT concentration
in lymph. The UC in discoidal HDLs isolated from the plasma of
subjects with familial LCAT deficiency is an efficient substrate for
the enzyme (Glomset et al., 1970). This is also true of UC acquired
by reconstituted HDL disks composed of phosphatidylcholine
(PC) and human apo AI (Nanjee et al., 1999), and of the UC in
HDL disks recovered from rat liver perfusates (Hamilton et al.,
1976). When infused intravenously into humans, apo AI/PC disks
acquire UC and are rapidly converted to CE-rich spheroidal
HDLs (Nanjee et al., 1999). And yet the discoidal HDLs formed in
interstitial fluid do not undergo such metabolism until after they
have entered the blood.
An understanding of the mechanism of the suppression of
cholesterol esterification in interstitial fluid may shed light on the
regulation of LCAT, and aid the development of new approaches
to the prevention of atherosclerosis by modulation of HDL
metabolism. In this the first study of the mechanism in humans,
we have tested several hypotheses by experiments in vitro
with normal human afferent lymph, which is representative of
interstitial fluid (Nanjee et al., 2000b, 2001).
MATERIALS AND METHODS
Subjects
Lymph from 20 healthy men was studied. Ages were 20–69 years
(mean, 34.5 years), body weights 60–97 kg (75 kg), body mass
indexes 19.3–28.4 kg/m2 (23.5 kg/m2), plasma total cholesterol
1.54–5.48 mmol/l (4.16 mmol/l), plasma HDL cholesterol
0.71–1.89 mmol/l (1.22 mmol/l), and plasma triglycerides 0.74–
3.26 mmol/l (1.36 mmol/l). Screening of the volunteers for health
status was as previously described (Nanjee et al., 2000b). All
subjects gave informed consent. The protocol had been approved
by the ethics committees of London Bridge Hospital and St
Bartholomew’s Hospital Medical School, London, where the
clinical and laboratory procedures were performed, respectively.
All subjects gave written informed consent.
Clinical Procedures
Interstitial fluid was collected as afferent (pre-nodal) peripheral
lymph from overnight-fasted subjects under metabolic ward
conditions by cannulation of a lymph vessel in the lower leg,
according to our previously described procedures (Nanjee et al.,
2000b). Lymph was collected for periods of 2 or 3 h into
plastic tubes containing 2 mg dry disodium EDTA (Nanjee et al.,
2000b). Flow rates were 0.10–2.0 ml/h (mean 0.78). Preliminary
studies had shown that collection into tubes containing an LCAT
inhibitor, or collection into tubes chilled in crushed ice, had
no effect on the UC/CE ratios of the samples (Nanjee et al.,
2000b; Cooke et al., 2004), indicating there was essentially no
esterification of cholesterol during the collection period. Venous
blood samples were collected into disodium EDTA (1 mg/ml) at
the mid-point of each lymph collection period, and placed into
crushed ice.
Laboratory Procedures
Blood and lymph samples were centrifuged immediately after
collection, as previously described (Nanjee et al., 2000b). The
supernatants were divided into aliquots, which were flash frozen
in liquid nitrogen, and then transferred to a freezer at −85◦C.
All assays were performed in duplicate, and the mean result
calculated. The details of the laboratory procedures used in
each experiment are provided as footnotes to the figures and
table.
RESULTS
Endogenous Cholesterol Esterification
Rate
In conformity with previous studies, the endogenous cholesterol
esterification rate (ECER) in lymph during incubation in vitro
averaged only 4.2% (P < 0.001) of that in plasma from the same
subjects (Table 1). The rate was not correlated with lymph LCAT
concentration (r = +0.06), lymph LCAT activity (r = –0.02), or
lymph apo AI concentration (r =+0.02).
LCAT Activity
LCAT activity in lymph assayed using a radio-labeled
proteoliposome substrate averaged 10.3% (P < 0.01) of that
in plasma (Table 1). It was positively correlated with both lymph
LCAT concentration (r =+0.93, P< 0.001; Figure 1) and lymph
apo AI concentration (r = +0.83, P < 0.001), but not with
plasma LCAT activity (r = +0.12). The correlation coefficient
between plasma LCAT activity and plasma LCAT concentration
was+0.78 (P < 0.001; Figure 1).
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TABLE 1 | Endogenous esterification rate, LCAT activity, LCAT concentration, LCAT specific activity, and apo AI concentration in lymph and plasma
samples from twenty healthy male subjects.
LCAT conc1
(µg/ml)
ECER2
(nmol/ml/h)
LCAT activity3
(nmol/ml/h)
LCAT sp activity4
(nmol/h/µg)
Apo AI conc5
(mg/ml)
UC conc6
(mmol/I)
Subject Lymph Plasma Lymph Plasma Lymph Plasma Lymph Plasma Lymph Plasma Lymph Plasma
1 0.84 5.24 2.13 69.6 13.5 103 16.1 19.7 0.24 1.02 0.13 1.17
2 0.71 6.46 3.70 69.3 12.8 126 18.0 19.5 0.19 0.85 0.05 1.02
3 1.06 6.20 2.01 37.6 20.4 119 19.2 19.2 0.32 1.19 0.14 1.01
4 0.54 6.26 2.62 57.0 10.4 132 19.3 21.1 0.13 0.77 0.06 1.06
5 0.58 6.05 1.27 48.2 7.40 104 12.8 17.2 0.17 0.86 0.05 0.86
6 1.08 7.08 2.26 44.7 14.9 105 13.8 14.9 0.19 0.82 0.08 0.80
7 0.76 8.62 3.52 68.5 10.1 141 13.3 16.4 0.20 1.29 0.10 1.30
8 0.96 8.55 3.62 83.3 12.0 133 12.5 15.5 0.23 0.87 0.10 1.16
9 1.32 8.19 4.60 46.1 20.9 155 15.8 18.9 0.30 0.97 0.09 0.90
10 0.68 6.34 4.19 70.6 7.30 131 10.7 20.7 0.17 0.99 0.07 0.94
11 0.37 6.86 2.88 57.3 5.00 125 13.5 18.3 0.09 0.90 0.04 1.04
12 1.32 7.42 1.77 58.4 23.8 132 18.0 17.8 0.33 1.18 0.11 0.89
13 0.84 6.99 1.54 57.0 13.5 129 16.1 18.4 0.17 0.81 0.13 1.11
14 0.74 8.78 2.28 65.2 11.2 179 15.1 20.3 0.28 1.51 0.07 1.05
15 1.66 7.91 3.16 66.4 24.2 141 14.6 17.8 0.34 0.91 0.23 1.08
16 0.61 4.95 1.38 52.3 10.3 96 16.9 19.4 0.16 0.78 0.07 0.94
17 0.71 10.9 1.25 68.6 8.90 154 12.5 14.2 0.13 0.87 0.05 1.31
18 0.79 7.96 5.10 79.3 10.9 142 13.8 17.8 0.28 1.62 0.10 1.63
19 0.88 8.98 2.93 76.4 15.0 146 17.0 16.3 0.26 1.47 0.13 1.30
20 1.21 8.86 1.04 77.1 17.1 134 14.1 15.1 0.24 1.05 0.07 0.87
Mean 0.88 7.43 2.66 62.6 13.5 131 15.2 17.9 0.22 1.04 0.09 1.07
SD 0.31 1.46 1.18 12.6 5.41 20 2.4 2.0 0.07 0.20 0.04 0.20
1LCAT concentration was measured using an ELISA kit provided by Daiichi Pure Chemicals, Japan, according to the procedures described by Kobori et al. (2002).
2For measurement of ECER, paired samples of plasma and lymph were incubated in vitro either in crushed ice or at 37◦C for 3 h, and then rapidly cooled to 0–4◦C in
crushed ice. The rate of esterification of cholesterol was calculated from the decrease in the concentration of UC (Albers et al., 1986) measured enzymatically (Nanjee
and Miller, 1996). 3LCAT activity was measured using an optimal proteoliposome substrate of apo AI, PC and 14[C]-labeled UC (molar ratio 1:300:10; Albers et al., 1986).
4 In each sample of lymph or plasma, LCAT specific activity was calculated by dividing LCAT activity by LCAT concentration. 5Apo AI concentration was measured by
immunoelectrophoresis as described by Nanjee et al. (2000a). 6The concentration of UC was quantified enzymatically (Nanjee and Miller, 1996). LCAT, lecithin:cholesterol
acyltransferase; ECER, endogenous cholesterol esterification rate; apo AI, apolipoprotein AI; sp activity, specific activity; UC, unesterified cholesterol; SD, standard
deviation. The values underlined are the highest and lowest in each column.
FIGURE 1 | Relation of LCAT activity to LCAT concentration in plasma
and lymph samples from 20 subjects. Assays were performed as
described in Table 1.
LCAT Concentration
Lymph LCAT concentration averaged 11.8% (P< 0.01) of plasma
LCAT concentration (Table 1). It was not significantly correlated
with plasma LCAT concentration (r = +0.26, P = 0.27), but
was correlated with lymph apo AI concentration (r = +0.80,
P < 0.001).
Specific Activity of LCAT
The specific activities of LCAT in lymph and plasma were
calculated by dividing the result obtained for LCAT activity by
that for LCAT concentration in the same sample. On average, the
specific activity in lymph was slightly lower than that in plasma
(P < 0.001; Table 1).
Apo AI and UC Concentrations
In agreement with previous studies, lymph apo AI concentration
averaged about 21% of plasma apo AI concentration (P < 0.001;
Table 1). The two were positively correlated (r = +0.54,
P = 0.013). The concentration of UC in lymph averaged 8.4%
(P < 0.001) of that in plasma (Table 1).
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Effect on ECER of Mixing Lymph with
Native or Heat-Inactivated Plasma
The ECER observed with various mixtures of lymph, buffer,
buffer containing fatty acid-free albumin, native human plasma,
and heat-inactivated human plasma are presented in Figure 2.
The result obtained with a mixture of lymph and native plasma
was essentially identical to that obtained with a mixture of
similar volumes of buffer and native plasma, providing evidence
that lymph does not contain a soluble inhibitor of cholesterol
esterification. The ECER observed during incubation of lymph
with heat-inactivated human plasma (i.e., in which LCAT had
been inactivated by incubation for 30 min at 56◦C, ref 20) was 11-
fold greater than that observed with a mixture of similar volumes
of lymph and buffer, demonstrating that the enzyme in lymph
was functional and able to catalyze the esterification of UC in
plasma HDLs. In the same series of incubations, addition of fatty
acid-free albumin had no effect on the ECER in lymph (Figure 2).
Effect of Adding Recombinant Human LCAT
When increasing amounts of recombinant human LCAT were
added to lymph, a linear increase in LCAT activity was recorded
(Figure 3). The slopes of the regression lines were similar to those
observed when LCAT was added to buffer, normal plasma, plasma
from a subject with familial LCAT deficiency (Nanjee et al., 2003),
or heat-inactivated plasma.
Effect on ECER of Triglyceride-Rich
Lipoproteins
We have reported that human lymph contains both CE
transfer protein (CETP) and CETP activity (Miller et al., 2013).
The principal recipient particles for cholesteryl esters (CEs)
transferred from HDLs by CETP in plasma are triglyceride-
rich lipoproteins (TGRLs) and low density lipoproteins (LDLs;
Fielding and Fielding, 1981). As LCAT activity is inhibited by CEs
(Chajek et al., 1980), and lymph contains almost no TGRLs and
few LDLs (Nanjee et al., 2000b, 2001), we tested the hypothesis
that LCAT in lymph is inhibited as a consequence of retention
of CEs in spheroidal HDLs. However, addition of neither the
d < 1.006 g/ml fraction of normal human plasma nor Intralipid
20% increased the ECER (Figure 4).
Effects of Adding Lipid-Free Apo AI, Apo
AI/PC disks, or Apo AI/PC/UC disks
Addition of delipidated human apo AI to lymph had no effect
on the ECER (Figure 5). By contrast, addition of discoidal
proteoliposomes composed of human apo AI in association with
PC increased the ECER during the first 2 h of incubation by 10-
fold (Figure 5). When similar incubations were carried out using
disks containing UC in addition to apo AI and PC, the ECER was
increased by only 6-fold (Figure 5).
DISCUSSION
This is the first study of the mechanism underlying the very
low rate of cholesterol esterification in human interstitial fluid
relative to plasma. We found that afferent lymph, which is
representative of interstitial fluid (Michel and Curry, 1999;
Nanjee et al., 2000b, 2001), contains active LCAT enzyme.
As expected, LCAT concentration was much lower than
in plasma. Nevertheless, when lymph was added to heat-
inactivated plasma, the enzyme catalyzed the esterification of
UC at a rate of more than 10-fold that in lymph alone,
FIGURE 2 | Effect on ECER of mixing lymph (100 µl) from five subjects with an equal volume of pooled normal plasma, heat-inactivated pooled
plasma, or fatty acid-free albumin (final conc 50 mg/ml). Note that the scale of the vertical axes in panels (A,B) differs from that in panels (C,D). The buffer
used was 50 mmol/l Tris-buffered saline, pH 7.4. Statistical differences are described in the text. CE, cholesteryl esters. Results are means and SEM.
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FIGURE 3 | Effects of adding recombinant human LCAT (rh-LCAT; 12.5 µl) on LCAT activity in samples of plasma and lymph from subjects with
normal and high HDL cholesterol concentrations, plasma from a subject with familial LCAT deficiency (Nanjee et al., 2003), plasma in which LCAT
had been heat-inactivated (30 min at 56◦C), and Tris-buffered saline, pH 7.4. LCAT activity was measured as described in the footnote to Table 1. Human
rh-LCAT was a generous gift from Dr John Parks (Miller et al., 1996).
FIGURE 4 | Effects on the unesterified cholesterol concentration (Nanjee and Miller, 1996) in lymph during 22.5 h of adding Intralipid 20% (Fresenius
Kabi, Clayton, NC; containing 200 g soybean oil/l; right panel) or the d < 1.006 g/ml fraction of fasted normal human plasma (plasma triglycerides,
1.4 mmol/l).
showing that LCAT concentration was not the rate-limiting
factor.
No evidence was obtained for a soluble inhibitor of LCAT in
lymph. First, when lymph was added to plasma, the ECER was
not reduced relative to that observed in plasma alone. Second,
when increasing concentrations of recombinant human LCAT
were added to lymph, the increments in enzyme activity were
similar to those observed when the same masses of LCAT were
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FIGURE 5 | ECER in lymph samples from five subjects as a function of
time following addition of Tris-buffered saline, fatty acid-free albumin
(final conc 50 mg/ml), apo AI/PC disks (1:150 molar ratio; final conc
0.66 mg apo AI/ml), or apo AI/PC/UC disks (1:150:10, final conc
0.66 mg apo AI/ml). Each incubation mixture was composed of 100 µl
lymph or Tris-buffered saline plus 100 µl of buffer or the test material. At the
end of the incubation, 10 µl aliquots were analyzed in duplicate for UC mass
(Nanjee and Miller, 1996). The disks were provided by Central Laboratory,
Swiss Red Cross, Bern, Switzerland. Results are means and SEM.
added to normal, heat-inactivated, or LCAT-deficient human
plasma.
The much lower concentration of UC in lymph than in
plasma raised the question of whether it was limiting the ECER.
However, this hypothesis was not compatible with the fact that
the lymph/plasma ratio in ECER was much lower than that in
UC concentration.
Thus, our evidence suggested that the low esterification rate
in lymph HDLs is owing to a property that renders them a poor
substrate for LCAT. This hypothesis was supported by the finding
that the initial ECER in lymph was increased 10-fold when
apo AI/PC disks were added. By contrast, we have previously
reported that addition of similar disks to plasma had no effect
on ECER (Nanjee et al., 1999). We cannot determine from our
data whether the additional esterification in lymph occurred
in the disks or the lymph HDLs. LCAT exists in association
with HDLs, and the affinity of discoidal HDLs for the enzyme
exceeds that of spheroidal CE-rich HDLs (Kosek et al., 1999). The
catalytic efficiency of LCAT is also normally greater on discoidal
HDLs (Kosek et al., 1999). Thus, it is likely that some UC and
LCAT moved from the lymph HDLs to the disks, followed by
esterification of UC on the disks. A similar sequence may explain
the esterification observed when lymph was mixed with heat-
inactivated plasma, the lymph HDLs acting as a donor of active
LCAT to drive the reaction in plasma HDLs. An alternative
possibility is that the disks (or plasma HDLs in the case of
heat-inactivated plasma) have a greater affinity for a dissociable
inhibitor of LCAT than lymph HDLs, thereby ‘cleansing’ the latter
and enabling the reaction to proceed. Theoretical possibilities
for inhibitors include oxidized lipids (Bielicki et al., 1996;
Kamiyama et al., 1998) and lysophosphatidylcholine (Smith
and Kuksis, 1980). However, the failure of delipidated apo AI
and fatty acid-free albumin, which bind oxidized lipids and
lysophosphatidylcholine (Navab et al., 2000; Ek-Von Mentzer
et al., 2001; Matsumoto et al., 2007), to produce even a small
increase in ECER argues against these possibilities.
As LCAT is inhibited by CEs (Fielding and Fielding, 1981),
the hypothesis was tested that the ECER in lymph is suppressed
by retention of CEs in HDLs secondary to the very low
concentrations of apo B-containing lipoproteins. While this
seemed unlikely given that lymph HDLs have a greater UC/CE
ratio and lower CE/apo AI ratio than plasma HDLs (Nanjee et al.,
2000b, 2001), the possibility remained that it was a contributing
factor in some HDL subclasses. However, the failure of the
d < 1.006 fraction to increase the ECER despite the presence of
CETP in lymph (Miller et al., 2013), albeit in low concentration,
argued against this mechanism.
The possibility that esterification in lymph HDLs is suppressed
by sphingomyelin, which inhibits LCAT (Bolin and Jonas, 1996),
also merits consideration, as the sphingomyelin/PC molar ratio is
greater in lymph than in plasma (Nanjee et al., 2000b). However,
the difference in ratio (0.33 vs. 0.28; Nanjee et al., 2000b) appears
too small to explain such a large difference in ECER.
On the basis of studies of apo AI epitopes in suction blister
fluid, Wong et al. (1992) concluded that apo AI in interstitial fluid
does not function as a cofactor for LCAT owing to a change in
conformation. This explanation would be compatible with some
of our findings. For it to be correct, however, the same change in
conformation would need to involve all HDL subclasses in lymph:
CE-rich alpha HDLs, lipid-poor pre-beta HDLs, and discoidal
HDLs (Nanjee et al., 2000a, 2001; Miller et al., 2013). This would
be surprising given that the conformation of apo AI already
differs among them. This mechanism would also not explain why
apos E and AIV, both of which are present in lymph (Nanjee
et al., 2000b) and have cofactor activity for LCAT (Bisgaier et al.,
1987; Gong et al., 1989; Emmanuel et al., 1994), do not maintain
esterification. The possibility exists that the findings of Wong
et al. (1992) were due to tissue disruption and release of proteases
during production of the blisters.
In contrast to the apo AI/PC disks, we found that disks with
the same apo AI/PC ratio that also contained UC were much
less effective in raising ECER. This would be consistent with
suppression of cholesterol esterification in lymph HDLs being
due to substrate inhibition. Substrate inhibition of LCAT at high
UC/PC ratios in HDLs, achieved by exposure to phospholipase
A2 (Chollet et al., 1986) or enrichment with UC (Simard et al.,
1989), has been observed in vitro. In studies with sonicated
dispersions of UC and PC, Nichols and Gong (1971) also found
that net esterification and initial reaction rate decreased with
increasing UC/PC ratio.
Thus, our findings suggest that esterification of UC in
interstitial fluid HDLs is suppressed as a consequence of substrate
inhibition by UC transferred from cells via ABCA1 transporters.
When lymph HDLs enter blood via the lymphatic vessels, the UC
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redistributes among plasma lipoproteins, thereby reducing the
inhibition and enabling esterification to proceed.
It is interesting to speculate on the function of substrate
inhibition in interstitial fluid. Kinetic analyses of apo AI after
intravenous apo AI/PC disks have indicated that HDLs remain
in the extracellular matrix on average for about 29 h before
entering the lymph vessels (Hovorka et al., 2006). Lymph is
virtually devoid of TGRLs (Nanjee et al., 2000b, 2001), the
principal recipients in plasma of CEs transferred via CETP
from HDLs. Thus, if UC delivered to HDLs from cells via
ABCA1 transporters were continuously esterified, the increase
in the size of the particles consequent upon retention of CEs
might impede their passage through the interstices of the
matrix. An alternative or additional function might be to limit
the production of lysophosphatidylcholine in the presence of
albumin concentrations that are only one third of those in
plasma (Nanjee et al., 2000b), thereby protecting tissues from
its detergent and pro-inflammatory activities (Matsumoto et al.,
2007).
Our experiments used lymph collected from a vessel that
drains skin, connective tissue, and adipose tissue. As other
investigators have shown that reverse cholesterol transport from
arterial wall macrophages also occurs via lymphatic vessels (Lim
et al., 2013; Martel et al., 2013), our findings have implications
for strategies to prevent atherosclerosis by modulation of HDL
metabolism. If LCAT is inhibited upon entering interstitial
fluid in the artery wall, raising its concentration in plasma
pharmacologically or by intravenous infusion might not increase
eﬄux of UC from arterial macrophages, its effect being limited
to cells exposed directly to plasma (e.g., erythrocytes, liver
macrophages, spleen cells). This might explain why LCAT
transgenesis has failed to protect mice from atherosclerosis
(Bérard et al., 1997; Föger et al., 1999). Brousseau et al.
(2000) found that LCAT transgenesis also had no effect on
atherosclerosis in LDL receptor negative rabbits. Although it
did reduce lesions in cholesterol-fed LDL receptor positive
rabbits, this was dependent on an associated reduction of
LDL concentration. Van Craeyveld et al. (2009) observed
no significant effect of hepatocyte-directed adenoviral rabbit
LCAT gene transfer on atherosclerosis in cholesterol-fed
rabbits.
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